Cytomedix Inc. Announces Multiple Poster Presentations at the 44th Annual Conference of the Wound Ostomy Continence Nurses Society

GAITHERSBURG, MD--(Marketwire - June 08, 2012) - Cytomedix, Inc. (OTCBB: CMXI) (the “Company”), a regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair, today announced that four poster presentations highlighting the clinical merits of the Company’s AutoloGel™ System in wound management will be presented at the 44th Annual Conference of the Wound Ostomy and Continence Nurses Society (“WOCN®") being held in Charlotte, North Carolina from June 9-13, 2012.

The AutoloGel System, a device for the production of autologous platelet rich plasma (“PRP”) gel, is the only PRP device cleared by the U.S. Food and Drug Administration (“FDA”) for use in wound management.

The following posters highlighting Cytomedix’s PRP technology will be presented at WOCN 2012:

• Fistula and Pseudostoma Management Using Platelet Rich Plasma Gel by lead author Janice Wilson, RN, CWOCN, Karl Branch, RN, Asheville Specialty Hospital, Asheville, North Carolina. Poster Number 6241

• Calculating Saved Costs When Using Platelet-Rich-Plasma Gel in Place of NPWT in 17 Complex Wound Patients by lead authors Janice Wilson, RN, CWOCN and Karl Branch, RN, Asheville Specialty Hospital, Asheville, North Carolina. Poster Number 6240

• Response of Wounds of Spinal Cord Injured Persons to 1x Autologous Platelet Rich Plasma Gel by lead author Laurie M. Rappl, PT, DPT, CWS, Cytomedix, Inc., Gaithersburg, Maryland. Poster Number 6266

• The Impact of Autologous Platelet Rich Plasma Gel on Chronic Wounds by lead authors Carelyn P. Fylling, RN, MSN, CWS, CLNC, Cytomedix, Inc, Vice President of Professional Services, and Laurie M. Rappl, PT, DPT, CWS, Cytomedix, Inc. Clinical Development Liaison, Poster Number 6210
  

“This body of clinical data demonstrates AutoloGel’s ability to accelerate wound healing in common wound etiologies and also shows its effectiveness on fistulas, pseudostomas, and pressure ulcers in persons with spinal cord injury, which are all notoriously difficult to heal wounds. In addition, the data shows that AutoloGel saves money while increasing healing rates and decreasing staff time,” commented Carelyn P. Fylling, RN, MSN, CWS, CLNC, Cytomedix’s Vice President of Professional Services.

“We are pleased to have these four posters presented at WOCN as it offers an ideal venue to reach and educate a large audience of clinicians who specialize in wound management on the clinical merits of AutoloGel to heal these challenging wounds. These data, collectively and individually, demonstrate the clinical utility of AutoloGel to heal a variety of hard-to-heal wounds,” commented Martin P. Rosendale, Chief Executive Officer of Cytomedix. “Compelling clinical results such as these should favorably impact the adoption of AutoloGel in a variety of wounds and wound care settings, and further strengthen final negotiations with our potential top 20 global pharmaceutical partner.”

The posters will be available at WOCN as follows:

Sunday, June 10
6:30 am - 8:00 pm Poster Viewing

Monday, June 11
9:00 am - 5:30 pm Poster Viewing

Tuesday, June 12
7:00 am - 9:00 am Authors Session and Awards Presentation
9:00 am - 6:30 pm Poster Viewing

Wednesday, June 13
8:00 am - 12:00 pm Poster Viewing

About Cytomedix, Inc.
Cytomedix, Inc. is an autologous regenerative therapies company commercializing and developing innovative platelet and adult stem cell technologies for wound and tissue repair. The Company markets the AutoloGel™ System, a device for the production of autologous platelet rich plasma (“PRP”) gel for use on a variety of exuding wounds and the Angel® Whole Blood Separation System, a blood processing device and disposable products used for the separation of whole blood into red cells, platelet poor plasma (“PPP”) and PRP in surgical settings On February 8, 2012 Cytomedix closed the acquisition of Aldagen, a biopharmaceutical company developing regenerative cell therapies based on its proprietary ALDH bright cell (“ALDHbr”) technology, currently in a Phase 2 trial for the treatment of ischemic stroke. For additional information please visit www.cytomedix.com

Safe Harbor Statement
Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix’ actual results may differ materially due to a number of factors, many of which are beyond Cytomedix’ ability to predict or control, including among many others, risks and uncertainties related to ALD-401’s continuing to demonstrate regenerative capabilities in these upcoming trials, the Company’s ability to successfully manage and advance clinical development of ALD-401, the likelihood of positive reviews at 30 and 60 patient thresholds, the Company’s continuing ability to successfully integrate the Aldagen acquisition and underlying technologies the sustained interest and demand for the ALD-401 treatment option among stroke clinicians, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company’s sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company’s ability to raise additional capital and to continue as a going concern, and Cytomedix’s ability to execute on its strategy to market the AutoloGel™ System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as “believes”, “forecasted,” “projects,” “is expected,” “remain confident,” “will” and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report for the year ended December 31, 2011 and other subsequent filings. These filings are available at www.sec.gov.